Prognostic role of sentinel node biopsy in patients with thick melanoma: A meta-analysis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 5, 2012, Pages 560-565

  Rondelli, F ^a   Vedovati, M C ^a   Becattini, C ^a   Tomassini, G M ^a   Messina, S ^b   Noya, G ^a   Simonetti, S ^a   Covarelli, P ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Perugia General Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; FOLLOW UP; HUMAN; MELANOMA; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

EID: 84857310329     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04109.x     Document Type: Review

References (34)

1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
2. Gershenwald JE, Mansfield PF, Lee JE, Ross MI,. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma. Ann Surg Oncol 2000; 7: 160-165. (Pubitemid 30164687)
3. Cherpelis BS, Haddad F, Messina J, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001; 44: 762-766. (Pubitemid 32391162)
4. Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C,. Sentinel lymph node mapping for thick (≥4 mm) melanoma: should we be doing it? Ann Surg Oncol 2003; 10: 408-415. (Pubitemid 40486939)
5. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG,. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002; 9: 637-645. (Pubitemid 34857980)
6. Thompson JF, Shaw HM,. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol 2002; 9: 719-722.
7. Cecchi R, Buralli L, Innocenti S, Seghieri G, De Gaudio C,. Sentinel lymph node biopsy in patients with thick (= 4 mm) melanoma: a single-centre experience. J Eur Acad Dermatol Venereol 2007; 21: 758-761. (Pubitemid 46939046)
8. Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK,. Clinical node-negative thick melanoma. Arch Surg 2002; 137: 291-295. (Pubitemid 34207988)
9. Gutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is the most important prognostic factor for thick (≥4 mm) melanomas. J Dtsch Dermatol Ges 2008; 6: 198-203. (Pubitemid 351361065)
10. Jacobs IA, Chang CK, Salti GI,. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg 2004; 70: 59-62.
11. Nowecki ZI, Rutkowski P, Michej W,. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol 2008; 15: 2223-2234.
12. 4 melanoma? Cancer 2009; 115: 5752-5760.
13. Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL,. Prognostic implications of thick (≥4 mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002; 9: 754-761.
14. Amersi F, Morton DL,. The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg 2007; 41: 241-256.
15. Caracò C, Celentano E, Lastoria S, Botti G, Ascierto PA, Mozzillo N,. Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters. Ann Surg Oncol 2004; 11 (Suppl. 3): 198S-202S.
16. Perrott RE, Glass LF, Reintgen DS, Fenske NA,. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol 2003; 49: 567-588. (Pubitemid 37210267)
17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012. (Pubitemid 30214957)
18. Altman DG, Chalmers I, Egger M, Smith GD,. Systematic Reviews in Health Care: Meta-Analysis in Context, 2nd edn. Blackwell BMJ Books, London, UK, 2001.
19. Higgins JPT, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
20. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003; 10: 569-574. (Pubitemid 40486922)
21. Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 538-549.
22. Faries MB, Morton DL,. Surgery and sentinel lymph node biopsy. Semin Oncol 2007; 34: 498-508. (Pubitemid 350236309)
23. Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL,. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004; 17: 747-755. (Pubitemid 38843356)
24. Van Akkooi AC, de Wilt JH, Verhoef C, et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42: 372-380. (Pubitemid 43132893)
25. Testori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1 313 patients (SOLISM-IMI). Ann Surg Oncol 2009; 16: 2018-2027.
26. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T,. Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg 2002; 89: 1223-1227. (Pubitemid 36002537)
27. Covarelli P, Tomassini GM, Simonetti S, et al. The single-photon emission computed tomography/computed tomography: a new procedure to perform the sentinel node biopsy in patients with head and neck melanoma. Melanoma Res 2007; 17: 323-328. (Pubitemid 47462225)
28. Messina JL, Glass LF, Cruse CW, Berman C, Ku NK, Reintgen DS,. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999; 23: 686-690. (Pubitemid 29262832)
29. Frishberg DP, Balch C, Balzer BL, et al. Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 2009; 133: 1560-1567.
30. Mandalà M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer 2009; 45: 2537-2545.
31. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 2005; 12: 429-439. (Pubitemid 40884257)
32. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317. (Pubitemid 44465459)
33. Van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumour burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248: 949-955.
34. Balch CM,. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988; 6: 163-172. (Pubitemid 18040005)